On December 13, although the three major indexes all fell by more than 1%, the biomedical sector bucked the trend and strengthened, and among the more than 460 concept plates of the flush, the top eight were all biomedical subdivisions. New crown drugs, chemical pharmaceuticals, Alzheimer's concept, influenza, hyperbaric oxygen chamber, hepatitis concept, traditional Chinese medicine, and generic drugs are all in the market**. **From the point of view, Senxuan Pharmaceutical and Tuoxin Pharmaceutical are both 20cm daily limit;Jinling Pharmaceutical, Tonghua Jinma, Zhejiang Zhenyuan, Datang Pharmaceutical, etc. have increased the limitGuangshengtang, Xinhua Pharmaceutical, Menova, Qianyuan Pharmaceutical, Haichen Pharmaceutical, etc. followed suit. What is the reason for the full line of biomedical plates?What is the future trend?Which sectors have more opportunities?Let's listen to Xiao Miao's decomposition below.
Swipe!The pharmaceutical sector has a large-scale daily limit!
*From the Internet) On December 13, A-shares failed to continue the strength of the previous day, and the overall low opened low, and the Shanghai Composite Index fell below the 3,000-point integer mark at the opening, ** at 296876 points, **115%。However, the biomedical sector bucked the trend and strengthened. New crown special drug plate**317%, chemical pharmaceuticals, Alzheimer's concept, influenza, hyperbaric oxygen chamber, hepatitis concept, generic drugs, traditional Chinese medicine, etc. 
Data**: Straight flush.
Tuoxin Pharmaceutical, Senxuan Pharmaceutical 20cm daily limit;Baili Tianheng, Hengdi Pharmaceutical, and New Ganjiang** exceeded 10%;Jinling Pharmaceutical, Shapu Aisi, Tonghua Jinma and other strong sealing boards. On the news side, recently, a kind of name called jn1 of the COVID variant is spreading rapidly around the world and has been detected in 12 countries. According to health agencies in the United Kingdom and the United States, the variant is currently the fastest-growing COVID variant knownIt is expected to trigger a new wave of new coronavirus infections. Although, jnThe 1 variant is currently widely discussed on social media, but according to the virus mutation monitoring data of local cases in China from the Chinese Center for Disease Control and Prevention, the current mainstream virus in China is still eg5 variants. The incident spawned the demand for new crown drugs, which is why the new crown special drug sector rose sharply on the 13th. So why are chemical drugs, traditional Chinese medicine, and generic drugs all brushing up?Mainly because at the press conference of the National Health Insurance Administration held on December 13, Huang Xinyu, director of the Pharmaceutical Management Department of the National Health Insurance Administration, introduced that the new version of the medical insurance drug list will be officially implemented on January 1, 2024. What is the specific situation of the new version of the pharmaceutical and drug list?
Medical insurance cost control!6 rounds of burden reduction of 600 billion
*Originated from the Internet).
On December 13, the National Health Insurance Administration held a press conference to introduce the adjustment of the 2023 National Medical Insurance Drug Catalog. Huang Xinyu, director of the Department of Pharmaceutical Service Management of the National Health Insurance Administration, introduced at the press conference that this adjustment is shared126 drugs were newly added to the National Medical Insurance Drug Catalog, and 1 drug was transferred out of the catalog. 143 drugs outside the catalogue participated in the negotiation or bidding, of which 121 drugs were successfully negotiated or bidd, with a negotiation success rate of 846%，The average price reduction is 617%, the success rate and ** decline are basically the same as in 2022. After this round of adjustment, the total number of drugs in the national medical insurance drug list has reached 3,088, including 1,698 Western medicines and 1,390 Chinese patent medicinesThere are still 892 kinds of Chinese medicine decoction pieces. Combined with the negotiation of price reductions and medical insurance reimbursement factors, it is expected to reduce the burden on patients by more than 40 billion yuan in the next two years. After 6 rounds of adjustments, the National Health Insurance Administration has accumulated744 new drugs were added to the medical insurance list, covering the entire directory31 ** areas。Among them, 100 drugs for oncology have been negotiated and approved93 drugs for chronic diseases such as hypertension, diabetes, and mental illness. Most of the drugs included in the catalogue through negotiation are newly launched drugs with high clinical value in recent years, and a large number of drugs with new mechanisms and new targets have been included in the catalogue. In general, after 6 consecutive years of catalog adjustment since the establishment of the National Health Insurance Administration, the procedural rules have been improved, the evaluation and calculation have become more transparent, the expectations of enterprises for drugs have become more objective and rational, and the number of new drugs approved for marketing has increased year by yearThe number of new varieties added to the catalogue has further increased compared with last year, and the level of benefit for patients has steadily improved, which has also effectively boosted the confidence of the pharmaceutical industry in increasing R&D and innovation. According to reports,After 6 rounds of medical insurance cost control, patients can reduce their burden by more than 600 billion yuan. Although it is said that it reduces the burden on patients, do you feel that it is cheaper to see a doctor?
Seeing a doctor is getting more and more expensive, but hospitals are losing more and more moneyWhere did the money go?
*Originated from the Internet).
When the public was cheering for more drugs to enter the medical insurance catalog, Xiao Miao saw a netizen's comment, which was particularly heart-wrenching, and the content was like this: Although the drug ** has declined, the overall medical expenses are getting higher and higher, and I am becoming more and more untreatable!Do you feel the same way?
According to statistics, from the beginning of medical insurance cost control in 2017 to 2023, although the drug ** has declined,However, the average outpatient fee of hospitals in China has increased from 257Yuan rose to 394 yuan, and the per capita cost of hospitalization increased from 8890The 7 yuan block rose to 13545$2. But at the same time, the hospital is still losing money. According to the information released by the National Health Commission,In 2022, hospitals across the country will lose 1 trillion yuan, the hospital's ** expenditure reached 24 trillion.
Why is it that seeing a doctor is getting more and more expensive, while the hospital says it is losing more and more?Where the hell does the money go?
Xiao Miao will show you a set of data:China's medical device market broke through the 100 billion yuan mark in 2010, and this number is still growing. In 2018 alone, the value of imported devices reached 221$6.5 billion.
Nearly 90% of domestic high-end medical equipment has to be imported from abroad. Even among the medical equipment with a total value of more than 100,000 yuan, there are very few domestic brands.
It is precisely because of the absolute monopoly of the industry that major foreign companies will set prices at will, and all the best costs will be pressed on China's medical institutions. In order to improve the level of **, the hospital had to buy these expensive equipment, and the loss was naturally formed.
The increase in costs will naturally fall on the patient.
Students think about it, which time you can't see a doctor through the instrument, even the common cold has to be tested by blood, so almost every diagnosis and treatment will use medical equipment, and this part of the cost is difficult to reimburse.
In addition, China's reimbursement mechanism is not reported if it does not reach the minimum payment line, does not report if it exceeds the cap line, and does not report the self-paid and self-paid parts. Self-payment means that the most expensive high-end drugs and projects are not reimbursed, and self-payment means that the reimbursement ratio is limited.
The above is the reason why patients are getting more and more expensive to see a doctor, while hospitals have been losing money, that is to say, most of the money has gone into the pockets of foreign medical device manufacturers. Therefore, China's medical device manufacturers still have a long way to go.
But then again, what are the investment opportunities that the upcoming implementation of the new drug catalogue will bring?
Which segments have the greatest opportunities?
*Originated from the Internet).
At the 2023 ** Economic Work Conference, ** proposed to buildBiomanufacturing, commercial aerospace, low-altitude economy and other strategic emerging industries, open up quantumLife Sciencesand other new tracks for future industries. This is really good for the development of the pharmaceutical industry. What's more, after a series of medical anti-corruption actions this year, the pharmaceutical sector has continued to adjust, and the current valuation is about 29 times, which is a lot lower than the 50 times from the high point, so the valuation has basically bottomed out. For the investment opportunities in the biomedical segment, Xiao Miao suggested that the students should make a long-term layout around the sectors that benefit from the policy. The first is the traditional Chinese medicine sectorThe launch of new drugs is accelerating, and the market is expected to expand further. It is recommended to explore investment opportunities in the field of industry consolidation and pediatric drugsThe second is the innovative drug sectorThe financing environment is expected to improve in 2024, and "going overseas" will bring incremental markets. It is recommended to select innovative drug companies with R&D strength and the expectation of "going overseas".The third is the AI + medical sector:Technology empowerment policies are favorable. It is recommended to pay attention to AI medical services, AI medical imaging, AI drug research and development, AI health management, AI genetic testing and other fields. Fourth, the first medical device sector:The growth is promising, focusing on enterprises with rich production lines and strong R&D capabilities. Therefore, the biomedical sector is at the bottom of history from both the policy and technical aspects, and there is a lot of room for the future. The above analysis is for reference only and is not intended as an investment basis